Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3427605 | 1.00 | EGFR (0.43) | EGFRSRCSCN9AALDH1A1HPGD | |
| SCHEMBL3399719 | 0.76 | POLB (0.60) | SCN9AALDH1A1SLC2A1 | |
| SCHEMBL3399725 | 0.76 | POLB (0.60) | SCN9AALDH1A1SLC2A1 | |
| SCHEMBL3290733 | 0.76 | POLB (0.51) | ALDH1A1SLC2A1TERT | |
| SCHEMBL3298450 | 0.71 | KAT2B (0.44) | ALDH1A1SLC2A1TERTDNM1 | |
| SCHEMBL3519650 | 0.70 | CACNA2D1 (0.40) | SLC2A1 | |
| SCHEMBL9588712 | 0.70 | SLC2A1 (0.42) | EGFRSCN9AALDH1A1SLC2A1 | |
| Biscryptolepine SCHEMBL30192568 | 0.70 | TERT (0.54) | ALDH1A1HPGDSMN1; SMN2TERTHSD17B10 | |
| SCHEMBL5811815 | 0.70 | TERT (0.40) | ALDH1A1HPGDSMN1; SMN2TERT | |
| SCHEMBL3292083 | 0.70 | RAD52 (0.47) | SLC2A1TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100129800-A1 | POLYMERS AND THEIR USE AS FLUORESCENT LABELS | AYMAMI BOFARULL JUAN | 2010-05-27 | — | — | US | disclosed |
| EP-2014698-A1 | Polymers and their use as fluorescent labels | Crystax Pharmaceuticals S.L. (ES) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100129800-A1 | POLYMERS AND THEIR USE AS FLUORESCENT LABELS | CBR3, H1-0, H1-3 | EGFR 1939/4885SRC 3966/4885SCN9A 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.